A new study published in The Journal of Dermatology revealed that patients with palmoplantar pustulosis (PPP) who were 18 ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

AbbVie bought rights to risankizumab from Boehringer Ingelheim in 2015, and is also testing it in other immunological disorders such as Crohn’s disease, psoriatic arthritis and asthma.

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

The older medication also represents an acceptable option for patients with skin psoriasis and psoriatic arthritis ... every 12 weeks with a drug like risankizumab [Skyrizi]," she said.

EULAR 2019 Interleukin-17 Edges TNF Inhibitor in Psoriatic Arthritis Early outcomes for ... 2019 Alert European Commission Approves Risankizumab for Plaque Psoriasis In clinical studies, patients ...

“Psoriatic arthritis is a complex disease involving ... Boehringer Ingelheim/AbbVie’s IL-23-targeting Skyrizi (risankizumab), Eli Lilly’s IL-17 blocker Taltz (ixekizumab) and Pfizer's ...